These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38798213)

  • 1. Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition.
    Patil SM; Mahadik I; Bhandari SV; Asgaonkar KD; Randive VD; Edake AM
    Curr Drug Discov Technol; 2024 May; ():. PubMed ID: 38798213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
    Patel P; Patel VK; Singh A; Jawaid T; Kamal M; Rajak H
    Curr Comput Aided Drug Des; 2019; 15(2):145-166. PubMed ID: 29732991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.
    Kankanala J; Latham AM; Johnson AP; Homer-Vanniasinkam S; Fishwick CW; Ponnambalam S
    Br J Pharmacol; 2012 May; 166(2):737-48. PubMed ID: 22141913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of New Quinazoline Derivatives as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-proliferative Studies.
    Dhawale SA; Dabhade PS; Mokale SN
    Anticancer Agents Med Chem; 2023; 23(18):2042-2055. PubMed ID: 37455449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR and Molecular Docking Studies of Oxadiazole-Ligated Pyrrole Derivatives as Enoyl-ACP (CoA) Reductase Inhibitors.
    Asgaonkar KD; Mote GD; Chitre TS
    Sci Pharm; 2014; 82(1):71-85. PubMed ID: 24634843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
    Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
    Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches.
    Bakal RL; Jawarkar RD; Manwar JV; Jaiswal MS; Ghosh A; Gandhi A; Zaki MEA; Al-Hussain S; Samad A; Masand VH; Mukerjee N; Nasir Abbas Bukhari S; Sharma P; Lewaa I
    Saudi Pharm J; 2022 Jun; 30(6):693-710. PubMed ID: 35812153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
    Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
    Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.
    Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
    Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
    Jarapula R; Badavath VN; Rekulapally S; Manda S
    Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-Cancer Studies.
    Dhawale SA; Mokale SN; Dabhade PS
    Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38185893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of GA-MLR for QSAR Modeling of the Arylthioindole Class of Tubulin Polymerization Inhibitors as Anticancer Agents.
    Ahmadi S; Habibpour E
    Anticancer Agents Med Chem; 2017; 17(4):552-565. PubMed ID: 27528182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies.
    Fouad MA; Osman AA; Abdelhamid NM; Rashad MW; Nabawy AY; El Kerdawy AM
    BMC Chem; 2024 Feb; 18(1):29. PubMed ID: 38347617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Research for Quinazoline-2,4-diones as HPPD Inhibitors Based on 2D-MLR and 3D-QSAR Models.
    Fu Y; Sun YN; Cao HF; Yi KH; Zhao LX; Li JZ; Ye F
    Comb Chem High Throughput Screen; 2017; 20(9):748-759. PubMed ID: 28637410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.